Abstract
Background: Cancer is one of the deadliest diseases at present. Although effective screening and treatment can save lives to a certain extent, our knowledge of the disease is far from sufficient. KIF18B is a member of the kinesin-8 superfamily and plays a conserved regulatory role in the cell cycle. KIF18B reportedly functions as an oncogene in some human cancers, but the correlations between KIF18B and prognosis and immune-infiltrates in different cancers remain unclear. Methods: Data were collected from the TCGA, GTEx, CCLE, TIMER, and GSEA databases. The expression difference, survival, pathological stage, DNA methylation, tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repairs (MMRs), tumor microenvironment (TME), immune cell infiltration, and gene co-expression of KIF18B were analyzed using the R language software. Results: KIF18B was widely upregulated in cancers, compared with normal tissues, and high KIF18B expression was associated with unfavorable prognoses. TMB, MSI, MMRs, and DNA methylation correlated with KIF18B dysregulation in cancers. KIF18B correlated closely with tumor immunity and interacted with different immune cells and genes in different cancer types. Conclusion: KIF18B could be used as a prognostic biomarker for determining prognosis and immune infiltration in pan-cancer.
Highlights
Tumors have gradually become the leading cause of death in the world (Bray et al, 2018)
Samples were separated into a high group and a low group according to the median expression of KIF18B, and the Gene Set Enrichment Analysis (GSEA) software was used to enrich the gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway
We extracted the mRNA levels of KIF18B from 33 cancer types in The Cancer Genome Atlas (TCGA) and plotted a box diagram of the expression of KIF18B in cancerous and adjacent tissues
Summary
Tumors have gradually become the leading cause of death in the world (Bray et al, 2018). With the continuous and relentless development of medical technology, tumor screening and treatment are constantly and significantly improving. The roles of the tumor microenvironment (TME) and host immunity have become increasingly important, and the emergence of immune checkpoint inhibitors (ICIs) has brought promising perspectives to more patients (Topalian et al, 2016). With this increase in clinical applications, more effective targets must be found. Effective screening and treatment can save lives to a certain extent, our knowledge of the disease is far from sufficient. KIF18B reportedly functions as an oncogene in some human cancers, but the correlations between KIF18B and prognosis and immuneinfiltrates in different cancers remain unclear
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
